Janssen reports positive new clinical data for Velcade

Janssen has presented new clinical evidence that reinforces the efficacy and importance of Velcade (bortezomib) as a treatment for multiple myeloma.

Data announced at the annual meeting of the American Society for Hematology has demonstrated the survival benefits of higher cumulative dose levels of the drug, which is the market-leading frontline non-transplant treatment for eligible multiple myeloma.

It also showed significantly improved response rates and disease progression when used in combination with dexamethasone, while demonstrating its association with low rates of cardiotoxicity.

Professor Maria-Victoria Mateos, consultant physician of the Haematology Department at the University Hospital of Salamanca, said: "As our understanding of the efficacy and safety of bortezomib develops, so does our ability to extend and improve the lives of patients with multiple myeloma."

Velcade is approved in more than 90 countries and has been used to treat more than 450,000 patients worldwide.

It was ratified for an expanded indication in Europe earlier this year, allowing it to be used as an induction therapy before stem cell transplantation among multiple myeloma patients.